Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil

Breast Journal

Volumn 17, Issue 6, 2011, Pages 657-660

  Li, Jun Jie ^a   Di, Gen Hong ^a   Tang, Li Chen ^a   Yu, Ke Da ^a   Hu, Zhen ^a   Liu, Guang Yu ^a   Lu, Jing Song ^a   Wu, Jiong ^a   Han, Qi Xia ^a   Shen, Zhen Zhou ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

breast cancer; epirubicin; pirarubicin; survival

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PIRARUBICIN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 80755153211     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01158.x     Document Type: Article

References (13)

1. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P,. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502-8. (Pubitemid 28506760)
2. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y,. 4″-O- tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 1982; 42: 1462-7. (Pubitemid 12148791)
3. Majima H, Iguchi H, Tone H,. Pharmacokinetic studies of THP-ADM (tetrahydropyranyl adriamycin). Gan To Kagaku Ryoho 1986; 13: 542-8.
4. Dantchev D, Bourut C, Maral R,. Cardiotoxicity and aiopecia of 12 different anthracyclines and 1 anthracycline in the golden hamster model. Proc Int Congr Chemother 1983; 211: 15-9.
5. Lenk H, Tanneberger S, Wiener N, et al. Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients. Oncology 1990; 47: 97-100. (Pubitemid 20075543)
6. Spielmann M, Kerbrat P, Delozier T, et al. Pirarubicin in advanced breast cancer: a French cooperative phase II study. Eur J Cancer 1990; 26: 821-3. (Pubitemid 20328557)
7. Enomoto K, Abe O, Tominaga T, et al. Clinical study of pirarubicin for breast cancer in Japan. Clinical Study Group of THP for Breast Cancer in Japan. Am J Clin Oncol 1990; 13 (Suppl. 1): 48-53.
8. Yamada K, Shirakawa S, Ohno R, et al. A phase II study of (2″R)-4″-0-tetrahydropyranyladriamycin (THP) in hematological malignancies. Invest New Drugs 1987; 5: 299-305. (Pubitemid 17130929)
9. Saito T, Kasai Y, Wakui A, et al. Phase II study of (2″R)-4″- O-tetrahydropyranyladriamycin (THP) in patients with solid tumors. Multi-Institutional Cooperative Study. Gan To Kagaku Ryoho 1986; 13: 1060-9. (Pubitemid 17217776)
10. Rapoport BL, Falkson G,. Phase II clinical study of pirarubicin in hormone resistant prostate cancer. Invest New Drugs 1992; 10: 119-21.
11. Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP,. Phase II trial of 4″-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma. Cancer 1992; 70: 1591-7.
12. Tominaga T, Abe O, Enomoto K, et al. A randomized controlled study of (2″R)-4″-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Biomed Pharmacother 1989; 43: 271-8. (Pubitemid 19153979)
13. Budisic Z, Predrijevac H, Podolski P, Gosev M,. Comparative study: pirarubicin vs doxorubicin in combination with cyclophosphamide and fluorouracil in the treatment of breast cancer. Eur J Cancer 1995; 31: 83-4.